In today’s briefing:
- Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps
- SK Biopharmaceuticals (326030 KS): Resumption of US Sales Growth Raises Hope for Annual Profit
Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps
- In this insight, we discuss the additional financing requirements, changed shareholding structure, and the next steps for Eoflow.
- Eoflow is one of the best performing stocks in the Korean stock market in the past one month as its shares have soared 249% in this period.
- The details of the oral argument (Insulet vs Eoflow) at the U.S. Appellate Court suggest that the U.S. Appellate Court may rule in favor of Eoflow.
SK Biopharmaceuticals (326030 KS): Resumption of US Sales Growth Raises Hope for Annual Profit
- In 1Q24, SK Biopharmaceuticals (326030 KS) posted Xcopri U.S. sales of KRW90.9B, up 69% YoY and 17% QoQ. The company remains confident to meet annual sales guidance of KRW390–416B.
- 1Q24 operating profit reached KRW10B from an operating loss of KRW23B in 1Q23. The company aims to achieve profitability throughout 2024.
- The company is seeking a second product to strengthen its U.S. and global business. Xcopri also has potential for indication expansion in near future.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
